Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- New Data Confirms Levemir's Efficacy for Type 1 Diabetes in Children Aged 2-5: Novo Nordisk
May 23, 2011
- Takeda Aims for Recovery through Shift toward New Products
May 23, 2011
- Prescriptions Filled by Growell HD Up 40%
May 23, 2011
- 39% of Hospitals Return to Black
May 23, 2011
- Takeda's Patents Cited in Largest Number of Notices of Reasons for Patent Refusal
May 23, 2011
- Teva to Buy 57% Stake in Taiyo for ¥37 Bil.
May 23, 2011
- Domestic Sales of New Drugs Contribute to Growth: Otsuka HD
May 23, 2011
- Daiichi Sankyo: Growth in Sales, Double-digit Rise in Profits
May 23, 2011
- Korosho Asks Kyokai-kenpo to Further Promote Use of Generics
May 23, 2011
- Astellas: Sales, Profits Down on Lower Overseas Sales of Prograf, Harnal
May 23, 2011
- Generics Market Share Up to 23.1% in FY2010 3rd Qtr: JGA
May 23, 2011
- Eisai: Sales Down for First Time in 12 Fiscal Years
May 23, 2011
- PMDA Committee to Offer Proposals to Shorten Pre-review Period
May 23, 2011
- Achieving CO2 Emissions Target to Remain Priority in FY2011: JPMA
May 23, 2011
- PMDA Introduces 12-Team System to Evaluate ADR Information
May 23, 2011
- Foreign-affiliated Drug Companies Outgrow the Market in Japan
May 23, 2011
- Lurasidone Fails to Show Efficacy in Pan-Asia PIII Study: DSP
May 23, 2011
- Top-4 Wholesalers' Operating Profit Rate Falls Below “Worst-ever”Levels Recorded 2 Years Ago
May 23, 2011
- Mucosta Superior to Hyaluronate in Improving Conjunctival Damage: Otsuka
May 23, 2011
- Operating Profits Down 60% for Ethical Drugs Wholesale Business: Medipal HD
May 23, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…